In this study, we find that the down-regulation of MAPK10 in HCC patients associates with poor survival prognosis, suggesting that MAPK10 might function as a prognostic factor and a potential therapeutic target for clinical treatment of HCC. This evidence concerns the gene MAPK10 and hepatocellular carcinoma.